Company profile
CYCLERION THERAPEUTICS, INC.
NASDAQ:CYCNBiotechnology: Pharmaceutical Preparations
Drug pipeline (2)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| OLINCIGUAT | phase2 | — | 5 | completed, terminated |
| PRALICIGUAT | phase2 | — | 7 | active |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (11)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT02906579 | phase2 | completed | 2016-09-01 | 2017-03-17 | Cyclerion Therapeutics | A Phase 2 Trial of IW-1973, A Stimulator of Soluble Guanylate Cyclase (sGC), in Patients With Stable Type 2 Diabetes and Hypertension |
| NCT03285178 | phase2 | completed | 2017-12-22 | 2020-07-22 | Cyclerion Therapeutics | A Study of the Effect of IW-1701 (Olinciguat), a Stimulator of Soluble Guanylate Cyclase (sGC), on Patients With Sickle Cell Disease (SCD) |
| NCT02792998 | phase1 | completed | 2016-05-01 | 2016-11-01 | Cyclerion Therapeutics | A Trial of IW-1701, A Stimulator of Soluble Guanylate Cyclase (sGC), in Healthy Subjects |
| NCT03499106 | phase1 | completed | 2018-04-12 | 2018-07-06 | Cyclerion Therapeutics | A Trial to Evaluate the Effect of Itraconazole (ITZ), a CYP3A4 Inhibitor, on the Pharmacokinetics of Praliciguat (IW-1973) in Healthy Volunteers |
| NCT03892499 | phase1 | completed | 2019-05-03 | 2019-06-23 | Cyclerion Therapeutics | A Trial to Evaluate the Effect of Itraconazole (ITZ), a CYP3A4 Inhibitor, on the Pharmacokinetics of the Soluble Guanylate Cyclase Stimulator, Olinciguat (IW-1701), in Healthy Volunteers |
FDA applications (0)
No records yet.